Matthew Gline - 15 Dec 2025 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
CEO, Director
Signature
By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline
Issuer symbol
ROIV
Transactions as of
15 Dec 2025
Net transactions value
-$36,853,839
Form type
4
Filing time
17 Dec 2025, 21:00:09 UTC
Previous filing
18 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gline Matthew CEO, Director C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline 17 Dec 2025 0001750094

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Options Exercise $950,430 +234,096 +1.4% $4.06 17,521,177 15 Dec 2025 Direct
transaction ROIV Common Shares Sale $4,994,140 -230,357 -1.3% $21.68 17,290,820 15 Dec 2025 Direct F1
transaction ROIV Common Shares Other $81,062 -3,739 -0.02% $21.68 17,287,081 15 Dec 2025 Direct F1, F2
transaction ROIV Common Shares Options Exercise $17,291,855 +1,363,711 +7.9% $12.68 18,650,792 15 Dec 2025 Direct
transaction ROIV Common Shares Sale $12,273,395 -566,116 -3% $21.68 18,084,676 15 Dec 2025 Direct F1
transaction ROIV Common Shares Other $17,291,860 -797,595 -4.4% $21.68 17,287,081 15 Dec 2025 Direct F1, F2
transaction ROIV Common Shares Options Exercise $28,819,763 +2,272,852 +13% $12.68 19,559,933 15 Dec 2025 Direct
transaction ROIV Common Shares Sale $20,455,665 -943,527 -4.8% $21.68 18,616,406 15 Dec 2025 Direct F1
transaction ROIV Common Shares Other $28,819,766 -1,329,325 -7.1% $21.68 17,287,081 15 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -234,096 -100% $0.000000 0 15 Dec 2025 Common Stock 234,096 $4.06 Direct F3
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -1,363,711 -100% $0.000000 0 15 Dec 2025 Common Stock 1,363,711 $12.68 Direct F3
transaction ROIV Stock Option (Right to Buy) Options Exercise $0 -2,272,852 -100% $0.000000 0 15 Dec 2025 Common Stock 2,272,852 $12.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934.
F2 Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
F3 Award of stock options to purchase Common Shares that is fully vested.